Dr. A P. Chen
Claim this profileNational Institutes of Health Clinical Center
Expert in Cancer
Studies Parotid Gland Cancer
25 reported clinical trials
68 drugs studied
About A P. Chen
Education:
- B.S. in Biomedical Engineering from Southeast University, China (1996).
- M.S. in Electrical Engineering from The Graduate School of Chinese Academy of Sciences, China (1999).
- Ph.D. in Electrical and Computer Engineering from Washington State University, Pullman, WA (2003).
- M.T.R. from the University of Pennsylvania, Philadelphia, PA (2012).
Experience:
- Postdoctoral Researcher in Radiology at the University of Pennsylvania, Philadelphia, PA (2005).
- Associate Professor at the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine.
- Associate Vice Chair of Artificial Intelligence at the University of Maryland School of Medicine.
- Senior member of the Institute of Electrical and Electronics Engineers (IEEE).
- Editorial member of several scientific journals.
- Principal Investigator for NIH-funded research.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
EWSR1/ATF1 positive
2Parotid Gland Cancer
Stage IV
Mismatch Repair Deficiency positive
Stage III
Affiliated Hospitals
Clinical Trials A P. Chen is currently running
Atezolizumab +/− Selinexor
for Sarcoma
This trial is testing if atezolizumab alone or with selinexor can shrink tumors in patients with a rare type of cancer called alveolar soft part sarcoma. Atezolizumab boosts the immune system to fight cancer, and selinexor stops cancer cells from growing. The goal is to see if these treatments work better than the usual care.
Recruiting1 award Phase 2
Talazoparib
for Advanced Cancer
This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response genes who have or have not already been treated with another PARP inhibitor. Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. All patients who take part on this study must have a gene aberration that changes how their tumors are able to repair DNA. This trial may help scientists learn whether some patients might benefit from taking different PARP inhibitors "one after the other" and learn how talazoparib works in treating patients with advanced cancer who have aberration in DNA repair genes.
Recruiting1 award Phase 219 criteria
More about A P. Chen
Clinical Trial Related2 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments A P. Chen has experience with
- Paclitaxel
- Atezolizumab
- Ipatasertib
- Talazoparib
- Biopsy
- Binimetinib
Breakdown of trials A P. Chen has run
Cancer
Parotid Gland Cancer
Soft Tissue Sarcoma
Ovarian Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does A P. Chen specialize in?
Is A P. Chen currently recruiting for clinical trials?
Are there any treatments that A P. Chen has studied deeply?
What is the best way to schedule an appointment with A P. Chen?
What is the office address of A P. Chen?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.